773869-09-3

Upstream product

• 121-33-5 vanillin 
• 32024-15-0 3,4-dimethoxy-5-iodobenzaldehyde 
• 5438-36-8 5-iodovaniline 

Downstream Products

• 1429785-96-5 2-amino-5-(3-iodo-4,5-dimethoxybenzyl)-6-methylpyrimidin-4-ol 
• 1429785-97-6 2-amino-5-(3-iodo-4,5-dimethoxybenzyl)-6-ethylpyrimidin-4-ol 
• 1429785-98-7 2-amino-5-(3-iodo-4,5-dimethoxybenzyl)-6-propylpyrimidin-4-ol 
• 1429785-99-8 5-(3-iodo-4,5-dimethoxybenzyl)-6-methylpyrimidine-2,4-diamine 
• 1429786-01-5 5-(3-iodo-4,5-dimethoxybenzyl)-6-ethylpyrimidine-2,4-diamine 
• 1429786-03-7 5-(3-iodo-4,5-dimethoxybenzyl)-6-propylpyrimidine-2,4-diamine 
• 1429786-07-1 (E)-3-(5-((2,4-diamino-6-methylpyrimidin-5-yl)methyl)-2,3-dimethoxyphenyl)-1-(1-propyl-phthalazin-2(1H)-yl)prop-2-en-1-one 
• 1429786-08-2 (E)-3-(5-((2,4-diamino-6-ethylpyrimidin-5-yl)methyl)-2,3-dimethoxyphenyl)-1-(propyl-phthalazin-2(1H)-yl)prop-2-en-1-one 
• 1429786-10-6 (E)-3-(5-((2,4-diamino-6-propylpyrimidin-5-yl)methyl)-2,3-dimethoxyphenyl)-1-(1-propyl-phthalazin-2(1H)-yl)prop-2-en-1-one 
• 1429786-11-7 (E)-3-(5-((2,4-diamino-6-methylpyrimidin-5-yl)methyl)-2,3-dimethoxyphenyl)-1-(isobutenylphthalazin-2(1H)-yl)prop-2-en-1-one 
• 1429786-12-8 (E)-3-(5-((2,4-diamino-6-ethylpyrimidin-5-yl)methyl)-2,3-dimethoxyphenyl)-1-(isobutenylphthalazin-2(1H)-yl)prop-2-en-1-one 
• 1429786-13-9 (E)-3-(5-((2,4-diamino-6-propylpyrimidin-5-yl)methyl)-2,3-dimethoxyphenyl)-1-(isobutenylphthalazin-2(1H)-yl)prop-2-en-1-one 
• 1432581-47-9 C₁₄H₁₅ClIN₃O₂ 
• 1429785-93-2 ethyl 2-(3-iodo-4,5-dimethoxybenzyl)-3-oxobutanoate 

Relevant academic research and scientific papers

Chemoselective zinc/HCl reduction of halogenated β-nitrostyrenes: Synthesis of halogenated dopamine analogues

A detailed account regarding the synthesis of 2- and 5-halogenated dopamine is given. The key step is a chemoselective reduction of a nitrostyrene by Zn/HCl at 0 °C. These conditions represent a simple, low-cost alternative to reduction by water-sensitive hydride donors and two-step procedures. Under these conditions, aryl fluoride, chloride, and bromide groups are stable. However, iodine undergoes significant reductive dehalogenation.

HIGHLY 6-SUBSTITUTED -2,4-DIAMINOPYRIMIDINES AS INHIBITORS OF ANTHRAX

2,4-diaminopyrimidine compounds of generic Formula 1, where R and R' may be the same or different and are independently selected from: C1-C6 alkyl or alkenyl groups with 1, 2, 3, 4, 5 or 6 carbon atoms, which may be: branched or unbranched; saturated or unsaturated; and may or may not be substituted, are used to treat anthrax.

Inhibition of Bacterial Dihydrofolate Reductase by 6-Alkyl-2,4-diaminopyrimidines

(±)-6-Alkyl-2,4-diaminopyrimidine-based inhibitors of bacterial dihydrofolate reductase (DHFR) have been prepared and evaluated for biological potency against Bacillus anthracis and Staphylococcus aureus. Biological studies revealed attenuated activity relative to earlier structures lacking substitution at C6 of the diaminopyrimidine moiety, though minimum inhibitory concentration (MIC) values are in the 0.125-8μgmL-1 range for both organisms. This effect was rationalized from three- dimensional X-ray structure studies that indicate the presence of a side pocket containing two water molecules adjacent to the main binding pocket. Because of the hydrophobic nature of the substitutions at C6, the main interactions are with protein residues Leu20 and Leu28. These interactions lead to a minor conformational change in the protein, which opens the pocket containing these water molecules such that it becomes continuous with the main binding pocket. These water molecules are reported to play a critical role in the catalytic reaction, highlighting a new area for inhibitor expansion within the limited architectural variation at the catalytic site of bacterial DHFR.